The Role of Genetic and Epigenetic Alterations in Neuroblastoma Disease Pathogenesis

Overview

Journal Pediatr Surg Int

Specialties General Surgery
Pediatrics

Date 2013 Jan 1

PMID 23274701

Citations 31

Authors

Raquel Domingo-Fernandez

Karen Watters

Olga Piskareva

Raymond L Stallings

Isabella Bray

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is a highly heterogeneous tumor accounting for 15 % of all pediatric cancer deaths. Clinical behavior ranges from the spontaneous regression of localized, asymptomatic tumors, as well as metastasized tumors in infants, to rapid progression and resistance to therapy. Genomic amplification of the MYCN oncogene has been used to predict outcome in neuroblastoma for over 30 years, however, recent methodological advances including miRNA and mRNA profiling, comparative genomic hybridization (array-CGH), and whole-genome sequencing have enabled the detailed analysis of the neuroblastoma genome, leading to the identification of new prognostic markers and better patient stratification. In this review, we will describe the main genetic factors responsible for these diverse clinical phenotypes in neuroblastoma, the chronology of their discovery, and the impact on patient prognosis.

Citing Articles

Prediction of Composite Clinical Outcomes for Childhood Neuroblastoma Using Multi-Omics Data and Machine Learning.

Wang P, Zhang J Int J Mol Sci. 2025; 26(1.

PMID: 39795994 PMC: 11720239. DOI: 10.3390/ijms26010136.

In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma.

Murphy C, Devis-Jauregui L, Struck R, Boloix A, Gallagher C, Gavin C PLoS One. 2024; 19(5):e0303643.

PMID: 38809883 PMC: 11135766. DOI: 10.1371/journal.pone.0303643.

Epigenetic Dysregulation in -Amplified Neuroblastoma.

Epp S, Chuah S, Halasz M Int J Mol Sci. 2023; 24(23).

PMID: 38069407 PMC: 10707345. DOI: 10.3390/ijms242317085.

Repurposing disulfiram, an alcohol-abuse drug, in neuroblastoma causes KAT2A downregulation and in vivo activity with a water/oil emulsion.

Beaudry A, Jacques-Ricard S, Darracq A, Sgarioto N, Garcia A, Rode Garcia T Sci Rep. 2023; 13(1):16443.

PMID: 37777587 PMC: 10543387. DOI: 10.1038/s41598-023-43219-2.

Characterization of m6A-related lncRNA signature in neuroblastoma.

Li L, Chen S, Li J, Rong G, Yang J, Li Y Front Pediatr. 2022; 10:927885.

PMID: 36324814 PMC: 9618704. DOI: 10.3389/fped.2022.927885.

References

McConville C, Reid S, Baskcomb L, Douglas J, Rahman N . PHOX2B analysis in non-syndromic neuroblastoma cases shows novel mutations and genotype-phenotype associations. Am J Med Genet A. 2006; 140(12):1297-301. DOI: 10.1002/ajmg.a.31278. View

Chen Y, Stallings R . Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res. 2007; 67(3):976-83. DOI: 10.1158/0008-5472.CAN-06-3667. View

Thompson P, Gotoh T, Kok M, White P, Brodeur G . CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene. 2003; 22(7):1002-11. DOI: 10.1038/sj.onc.1206211. View

Viswanathan S, Powers J, Einhorn W, Hoshida Y, Ng T, Toffanin S . Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009; 41(7):843-8. PMC: 2757943. DOI: 10.1038/ng.392. View

Celeste A, Difilippantonio S, Difilippantonio M, Fernandez-Capetillo O, Pilch D, Sedelnikova O . H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell. 2003; 114(3):371-383. PMC: 4737479. DOI: 10.1016/s0092-8674(03)00567-1. View

Devoto M, Specchia C, Laudenslager M, Longo L, Hakonarson H, Maris J . Genome-wide linkage analysis to identify genetic modifiers of ALK mutation penetrance in familial neuroblastoma. Hum Hered. 2011; 71(2):135-9. PMC: 3136385. DOI: 10.1159/000324843. View

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

Claviez A, Lakomek M, Ritter J, Suttorp M, Kremens B, Dickerhoff R . Low occurrence of familial neuroblastomas and ganglioneuromas in five consecutive GPOH neuroblastoma treatment studies. Eur J Cancer. 2005; 40(18):2760-5. DOI: 10.1016/j.ejca.2004.08.007. View

Viswanathan S, Daley G, Gregory R . Selective blockade of microRNA processing by Lin28. Science. 2008; 320(5872):97-100. PMC: 3368499. DOI: 10.1126/science.1154040. View

10.

Mraz M, Pospisilova S, Malinova K, Slapak I, Mayer J . MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma. 2009; 50(3):506-9. DOI: 10.1080/10428190902763517. View

11.

Ohira M, Kageyama H, Mihara M, Furuta S, Machida T, Shishikura T . Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line. Oncogene. 2000; 19(37):4302-7. DOI: 10.1038/sj.onc.1203786. View

12.

Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F . MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol. 2009; 42(3):312-9. DOI: 10.1165/rcmb.2009-0060OC. View

13.

Atroshchenko E, Karpova I, Cheshchevik A, KALININA L . [Effect of xanthinol niacinate on the autoimmunity and capillary permeability in patients with stable stenocardia]. Kardiologiia. 1991; 31(3):18-21. View

14.

Lin R, Lin Y, Yu A . miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol Carcinog. 2010; 49(8):719-27. DOI: 10.1002/mc.20647. View

15.

Brodeur G, Maris J, Yamashiro D, Hogarty M, White P . Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol. 1997; 19(2):93-101. DOI: 10.1097/00043426-199703000-00001. View

16.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

17.

Levine A . p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323-31. DOI: 10.1016/s0092-8674(00)81871-1. View

18.

Diskin S, Capasso M, Schnepp R, Cole K, Attiyeh E, Hou C . Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet. 2012; 44(10):1126-30. PMC: 3459292. DOI: 10.1038/ng.2387. View

19.

Bown N, Cotterill S, Lastowska M, ONeill S, Pearson A, Plantaz D . Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999; 340(25):1954-61. DOI: 10.1056/NEJM199906243402504. View

20.

Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H . Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst. 2006; 98(17):1193-203. DOI: 10.1093/jnci/djj330. View